Alerzin (levocetirizin) oral drops 5 mg/ml. 20 ml. vial

Description

Composition

active substance: levocetirizine dihydrochloride;

1 ml contains:

• 5 mg of levocetirizine dihydrochloride (corresponding to 4.21 mg of levocetirizine);

auxiliary substances: glycerin 85%, propylene glycol, sodium saccharin, sodium acetate trihydrate, methyl parahydroxybenzoate E 218), propyl parahydroxybenzoate (E 216), glacial acetic acid, purified water.

Medicinal form

Oral drops, solution.

Pharmacotherapeutic group

Antihistamines for systemic use. Piperazine derivatives. ATX code R06A E09.

Pharmacodynamics

Levocetirizine is an active, stable R-enantiomer of cetirizine, which belongs to the group of competitive histamine antagonists.

The pharmacological effect is due to the blocking of H1-histamine receptors.

Levocetirizine’s affinity for H1-histamine receptors is 2 times higher than that of cetirizine. It affects the histamine-dependent stage of the development of an allergic reaction, reduces the migration of eosinophils, vascular permeability, and limits the release of inflammatory mediators. Prevents the development and eases the course of allergic reactions, has an anti-exudative, anti-pruritic, anti-inflammatory effect, almost no anti-cholinergic and anti-serotonin effects. In therapeutic doses, it has almost no sedative effect.

Indication

• Symptomatic treatment of allergic rhinitis (including year-round allergic rhinitis) and urticaria.

Contraindications of Alerzin

• Hypersensitivity to levocetirizine or to any other component of this dosage form, or to any derivatives of piperazine.
• A severe form of chronic renal failure (creatinine clearance <10 ml/min).

Levocetirizine drops are quickly and intensively absorbed after oral administration. The degree of absorption of the drug does not depend on the dose of the drug and does not change with food intake, but the maximum concentration (Cmax) of the drug decreases and reaches its maximum value later. Bioavailability reaches 100%.

In 50% of patients, the effect of levocetirizine drops develops 12 minutes after taking a single dose, and in 95% – after 0.5-1 hour. Cmax in blood serum is reached 50 minutes after a single oral therapeutic dose and is maintained for 2 days. Cmax is 270 ng/ml after single use and 308 ng/ml after repeated use in a dose of 5 mg, respectively.